About 19,800 people die annually from MRSA (methicillin-resistant Staphylococcus aureus) in the United States alone. Many have already failed multiple antibiotic generations. For them, a tool is arriving that medicine discovered 100 years ago and then ignored for decades: bacteriophages, viruses that selectively kill bacteria. In January 2026, U.S. biotechnology company Armata Pharmaceuticals announced, following an end-of-Phase 2 meeting with the FDA, that it would advance its phage therapy candidate AP-SA02 into Phase 3 clinical trials. This is the first time worldwide that a phage preparation has reached this milestone in Western medicine.
What are phages?
Phages are natural viruses that exclusively infect bacteria. They recognize target cells through specific surface proteins, invade them, and destroy the bacterium from within. They are harmless to human cells. The idea of using phages medically dates back roughly 100 years and was continuously developed in the Soviet Union and Georgia, while Western medicine lost interest after discovering antibiotics.
Antibiotics have faced mounting pressure for decades: resistance develops faster than new drugs are approved. According to the WHO, about 16 percent of all laboratory-confirmed infections worldwide were antibiotic-resistant in 2023. In Southeast Asia and the Eastern Mediterranean, every third infection was already resistant. Globally, approximately 1.14 million people died directly from antibiotic-resistant infections in 2021.
The path from Phase 1 to Phase 3
Armata Pharmaceuticals is developing AP-SA02 as an intravenous cocktail of two naturally occurring lytic phage strains: ARSA0001 and ARSA0002. The FDA granted the candidate both Fast Track designation and Qualified Infectious Disease Product (QIDP) status, enabling expedited review and, if approved, five additional years of market exclusivity.
In October 2025, Armata presented Phase 2a results from the DISARM study at IDWeek, the leading U.S. infectious disease conference. The study enrolled 42 patients with complicated bacteremia from Staphylococcus aureus. Clinical response on day 12 of treatment was 88 percent in the AP-SA02 group versus 58 percent in placebo (p = 0.047). Relapse rates four weeks after therapy ended: zero percent in the treatment group, approximately 25 percent in control. In January 2026, the FDA completed this end-of-Phase-2 meeting. Armata announced plans to initiate Phase 3 in the second half of 2026.
In comparison: how other therapies found their path to approval
New therapeutic principles typically take decades to reach approval. Checkpoint inhibitors, T-cell-based immunotherapies for cancer, have been studied since the 1980s. Ipilimumab became the first approved checkpoint inhibitor for melanoma in 2011, transforming treatment for patients with no prior effective options. Today, checkpoint inhibitors are indispensable to oncology.
Another example: Hepatitis C was discovered in 1989. For decades, interferon was the only treatment, with cure rates of 40 to 50 percent and significant side effects. Sofosbuvir (Sovaldi) came to market in 2014. Today, over 95 percent of patients are cured in under twelve weeks. Phage therapy could follow a similar trajectory: an old idea, long neglected, now advancing through systematic clinical research toward practice.
MRSA causes approximately 19,800 deaths annually in the United States alone, according to the CDC, linked to around 120,000 bloodstream infections. In Germany, an estimated 132,000 MRSA cases are documented in hospitals yearly. Other biotech companies are pursuing similar approaches against other pathogens: Locus Biosciences is testing CRISPR-enhanced phage cocktail LBP-EC01 against antibiotic-resistant Escherichia coli infections in a Phase 2/3 study.
August 2029 at earliest: first commercial phage in Western medicine
Successful Phase 3 would be historic: the first commercially approved phage product in Western medicine. FDA approval, if Phase 3 succeeds, would be possible at earliest in 2028 or 2029.
Phage therapies have structural limitations: their spectrum is very narrow. A phage cocktail effective against MRSA does not work against other pathogens. Bacteria can also develop resistance to phages. For polymicrobial infections with multiple pathogens, phages fail as monotherapy. For the specific use case where antibiotics fail and patients have no alternative, an approved phage therapy would be a tool that intensive care physicians have awaited for decades.